APYX Quote, Financials, Valuation and Earnings

Baxter International has a net margin of -44.01% compared to Apyx Medical's net margin of 4.8%. Apyx Medical's return on equity of -140% beat Baxter International's return on equity of -7.38%.

Apyx Medical has a consensus price target of $4.00, signalling upside risk potential of 153.17%. On the other hand Baxter International has an analysts' consensus of $38.68 which suggests that it could grow by 24.17%. Given that Apyx Medical has higher upside potential than Baxter International, analysts believe Apyx Medical is more attractive than Baxter International.

Apyx Medical has a beta of 1.117, which suggesting that the stock is 11.729% more volatile than S&P 500. In comparison Baxter International has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.167%.

Apyx Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 2.95% to investors and pays a quarterly dividend of $0.17 per share. Apyx Medical pays -- of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend.

Apyx Medical quarterly revenues are $9.4M, which are smaller than Baxter International quarterly revenues of $2.6B. Apyx Medical's net income of -$4.2M is lower than Baxter International's net income of $126M. Notably, Apyx Medical's price-to-earnings ratio is -- while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical is 1.24x versus 1.34x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

electroCore has a net margin of -44.01% compared to Apyx Medical's net margin of -57.38%. Apyx Medical's return on equity of -140% beat electroCore's return on equity of -163.87%.

Apyx Medical has a consensus price target of $4.00, signalling upside risk potential of 153.17%. On the other hand electroCore has an analysts' consensus of $21.88 which suggests that it could grow by 342.37%. Given that electroCore has higher upside potential than Apyx Medical, analysts believe electroCore is more attractive than Apyx Medical.

Apyx Medical has a beta of 1.117, which suggesting that the stock is 11.729% more volatile than S&P 500. In comparison electroCore has a beta of 0.916, suggesting its less volatile than the S&P 500 by 8.354%.

Apyx Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. electroCore offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical pays -- of its earnings as a dividend. electroCore pays out -- of its earnings as a dividend.

Apyx Medical quarterly revenues are $9.4M, which are larger than electroCore quarterly revenues of $6.7M. Apyx Medical's net income of -$4.2M is lower than electroCore's net income of -$3.9M. Notably, Apyx Medical's price-to-earnings ratio is -- while electroCore's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical is 1.24x versus 1.41x for electroCore. Usually stocks with elevated PS ratios are considered overvalued.

KORU Medical Systems has a net margin of -44.01% compared to Apyx Medical's net margin of -12.1%. Apyx Medical's return on equity of -140% beat KORU Medical Systems's return on equity of -29.85%.

Apyx Medical has a consensus price target of $4.00, signalling upside risk potential of 153.17%. On the other hand KORU Medical Systems has an analysts' consensus of $5.50 which suggests that it could grow by 71.34%. Given that Apyx Medical has higher upside potential than KORU Medical Systems, analysts believe Apyx Medical is more attractive than KORU Medical Systems.

Apyx Medical has a beta of 1.117, which suggesting that the stock is 11.729% more volatile than S&P 500. In comparison KORU Medical Systems has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.809%.

Apyx Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KORU Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical pays -- of its earnings as a dividend. KORU Medical Systems pays out -- of its earnings as a dividend.

Apyx Medical quarterly revenues are $9.4M, which are smaller than KORU Medical Systems quarterly revenues of $9.6M. Apyx Medical's net income of -$4.2M is lower than KORU Medical Systems's net income of -$1.2M. Notably, Apyx Medical's price-to-earnings ratio is -- while KORU Medical Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical is 1.24x versus 4.20x for KORU Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Owlet has a net margin of -44.01% compared to Apyx Medical's net margin of -44.19%. Apyx Medical's return on equity of -140% beat Owlet's return on equity of --.

Apyx Medical has a consensus price target of $4.00, signalling upside risk potential of 153.17%. On the other hand Owlet has an analysts' consensus of $10.33 which suggests that it could grow by 94.6%. Given that Apyx Medical has higher upside potential than Owlet, analysts believe Apyx Medical is more attractive than Owlet.

Apyx Medical has a beta of 1.117, which suggesting that the stock is 11.729% more volatile than S&P 500. In comparison Owlet has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Apyx Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Owlet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical pays -- of its earnings as a dividend. Owlet pays out -- of its earnings as a dividend.

Apyx Medical quarterly revenues are $9.4M, which are smaller than Owlet quarterly revenues of $20.5M. Apyx Medical's net income of -$4.2M is higher than Owlet's net income of -$9.1M. Notably, Apyx Medical's price-to-earnings ratio is -- while Owlet's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical is 1.24x versus 0.76x for Owlet. Usually stocks with elevated PS ratios are considered overvalued.